Stangel M, Gold R
Neurologische Klinik, OE 7210, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625, Hannover.
Nervenarzt. 2011 Apr;82(4):415-6, 418, 420 passim. doi: 10.1007/s00115-010-3059-8.
Our knowledge on the clinical efficacy of intravenous immunoglobulins (IVIg) in neurological diseases has greatly increased in the last 5 years. Liquid formulations with a higher concentration of IVIg have simplified administration. Despite a worldwide increase in plasma production it is still a valuable biological product which is why current indications must be continuously validated. Long-term efficacy of the preparation Gamunex could be demonstrated in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). In acute myasthenic worsening a dose of 1 g IVIg/kg body weight appears to be sufficient for clinical stabilization. New indications, such as the postpolio syndrome or Alzheimer's disease are being explored in clinical trials. In addition to the consensus statement from 2004 the evidence for clinical use of IVIg has been re-evaluated and recommendations are given.
在过去5年里，我们对静脉注射免疫球蛋白（IVIg）治疗神经疾病的临床疗效的了解有了大幅增加。更高浓度IVIg的液体制剂简化了给药方式。尽管全球血浆产量有所增加，但它仍是一种有价值的生物制品，这就是为什么当前的适应证必须不断得到验证。Gamunex制剂对慢性炎症性脱髓鞘性多发性神经病（CIDP）患者的长期疗效已得到证实。在急性重症肌无力加重期，1 g IVIg/kg体重的剂量似乎足以实现临床稳定。诸如小儿麻痹后遗症或阿尔茨海默病等新的适应证正在临床试验中进行探索。除了2004年的共识声明外，还重新评估了IVIg临床应用的证据并给出了建议。
